THU0375 Quality of life in indian patients with systemic lupus erythematosus in durable remission: psychosocial and demographic factors

Background Remission in systemic lupus erythematosus (SLE) is uncommon. Detrimental effect of disease activity on quality of life (QoL) is reported but literature on QoL in lupus patients in durable remission is scant. Objectives To study QoL in Indian SLE patients in durable remission Methods We retrospectively included female SLE patients fulfilling ≥4 SLICC Classification Criteria, followed regularly at our clinic, who were in durable remission as determined by European consensus criteria (complete/clinical remission ±immunosuppressive drugs). QoL was assessed with Medical Outcomes Study Short-Form-12 (SF-12). We also collected data on demographics (age, duration of disease, years of education), duration and quality (complete versus clinical) of remission and patient reported fatigue through fatigue severity scale (FSS). A structured interview with a clinical psychologist using ICD-10 Diagnostic Criteria for Research (DCR) was performed to diagnose depression. Age matched female control subjects were also included and underwent similar exercises. Association of physical and mental component summary scores (PCS and MCS) of SF-12 with depression, quality and duration of remission, duration of disease, years of education and FSS were tested with generalised linear models using Gamma regression with log-link function. Results We included 106 female SLE patients (age: 28.9±7.6 years; duration of disease: 45.1±34.8 months; years of education: 9.6±5.2; depression present in 41 (38.7%)) and 98 female controls (age: 30.4±7 years; years of education: 10.8±6.2; depression present in 32 (32.7%)). At last visit, clinical remission was present in 68 (64.2%) and complete remission in 38 (35.2%). Duration of remission achieved were: 3 years in 31 (29.2%). Steroid-free remission was present in 64 (60.37%) and the rest 42 (39.62%) were on ≤5 mg/d prednisolone. All were on hydroxychloroquine. A stable dose of 2nd immunosuppressive drug was present in 54 (50.94%) with 3 on stable dose of mycophenolate and 51 on azathioprine. SLE patients had comparable SF-12 PCS (48.4±8.1 vs 47.1±7, p=0.098) and MCS (57.7±3.4 vs 56.6±5.6, p=0.199) as compared to controls. Among lupus patients, both PCS (r=– 0.616, p Conclusions Indian lupus patients in durable remission had similar physical and mental QoL compared to healthy controls. Physical QoL was better in patients with complete remission, longer disease duration and low fatigue. Mental QoL was better in patients with low fatigue, less education and longer disease duration. Disclosure of Interest None declared